![]() | |
Company type | Public limited company |
---|---|
LSE: ONT | |
ISIN | GB00BP6S8Z30 |
Industry | Nanopore sequencing |
Founded | 2005 |
Founders |
|
Headquarters | , |
Key people |
|
Revenue | ![]() |
![]() | |
![]() | |
Website | nanoporetech |
Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules. [2] [3] [4] It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. [5]
The company was founded in 2005 as a spin-out from the University of Oxford by Hagan Bayley, [6] Gordon Sanghera, and Spike Willcocks, with seed funding from the IP Group. [7] The company made an initial public offering on the London Stock Exchange on 30 September 2021, under the ticker ONT. [8]
In March 2016 the company announced a chemistry upgrade to its nanopore sequencing product 'R9', using a protein nanopore in collaboration with the laboratory of Han Remaut (VIB/Vrije Universiteit Brussel). [9] The company stated in a webcast that R9 is designed to improve error rates and yield. [10]
In July 2016, a MinION nanopore sequencer was included on the ninth NASA/SpaceX commercial cargo resupply services mission to the International Space Station. [11] The aim of the mission was to provide proof of concept for the MinION's functionality in a microgravity environment. [12] During the mission, ISS crew members successfully sequenced DNA from bacteria, bacteriophage and rodents from samples prepared on Earth. [13] Maintaining the MinION device as a research facility on the space station holds the potential to support a number of additional science investigations, any of which could have Earth based applications. [14]
The main products of Oxford Nanopore are:
These products are intended to be used for the analysis of DNA, RNA, proteins and small molecules with a range of applications in personalized medicine, crop science, and scientific research. [3] [28]